Table 2:

Random-effects logistic regression analysis of the effect of a 5-FC-containing treatment regimen compared to any other regimen on in-hospital mortality among HIV-seropositive patients with CM, July 2018-March 2020

Variable	Alive N=1033 n (%)	Died N=494 n (%)	Unadjusted OR for mortality (95% CI)	p-value	Adjusted OR for mortality (95% CI)	Wald p-value
Treatment regimen
Other regimen	586 (63)	351 (37)	ref
5-FC-containing regimen	447 (76)	143 (24)	0.53 (0.42-0.67)	<0.001	0.47 (0.35-0.64)	<0.001
Age category, years
≥18-29	193 (69)	85 (31)	ref
30-39	495 (74)	178 (26)	0.82 (0.60-1.11)	0.20	1.04 (0.71-1.51)	0.85
40-49	241 (62)	150 (38)	1.41 (1.02-1.96)	0.04	1.81 (1.221-2.70)	0.004
≥50	103 (56)	80 (44)	1.76 (1.20-2.60)	0.004	2.05 (1.26-3.34)	0.004
Sex
Male	606 (67)	295 (33)	ref
Female	427 (68)	199 (32)	0.96 (0.77-1.19)	0.70	1.22 (0.93-1.59)	0.15
CD4+ T-cell count (cells/μl)
<100	760 (66)	384 (34)	ref
≥100	219 (78)	60 (22)	0.54 (0.40-0.74)	<0.001	0.42 (0.75-0.61)	<0.001
Antiretroviral treatment status
Naïve	378 (66)	193 (34)	ref
Experienced	649 (69)	285 (31)	0.86 (0.69-1.07)	0.184	1.00 (0.75-1.32)	0.98
Altered mental status (GCS of <15)
No	749 (76)	239 (24)	ref
Yes	189 (50)	189 (50)	3.13 (2.44-4.02)	<0.001	3.00 (2.25-4.00)	<0.001
Concurrent TB treatment
No	764 (70)	330 (30)	ref
Yes	259 (63)	149 (37)	1.33 (1.05-1.69)	0.02	1.24 (0.91-1.67)	0.17

Data are n (%) or n (%)/N. 5-FC=flucytosine. CI=confidence interval. GCS=Glasgow Coma Scale score. OR=odds ratio. TB=tuberculosis